XOMA Royalty Announces Closing of Its Acquisition by Ligand
XOMA Royalty said Ligand Pharmaceuticals (Nasdaq: LGND) completed its acquisition of XOMA Royalty. Under the April 27 deal, XOMA shareholders received $39.00 cash per share and one non-transferable CVR per share tied to 75% of net proceeds from certain pending litigation. XOMA shares no longer trade on Nasdaq.
How this was made
The 30-second read
Why it matters
XOMA is effectively exiting public trading via acquisition completion, while both parties now face the practical and legal timeline around the CVR tied to pending litigation.
Market read
The close confirms cash-out terms ($39.00 per share) and signals a shift from merger arbitrage to CVR and litigation-linked outcomes.
What to watch
CVR is non-transferable and tied to 75% of net proceeds from pending litigation, so holder experience and timing of CVR payments could drive residual post-close trading/valuation.
Background
Ligand agreed to acquire XOMA Royalty on April 27, 2026; this release confirms the transaction has now closed.
Ticker impact
XOMA Royalty announced Ligand completed its acquisition, paying $39.00 per share and ending XOMA’s Nasdaq trading.
Near-term trading impact should be limited post-close; focus shifts to CVR mechanics and any remaining settlement/holder processing.
The article states the acquisition has completed, cash consideration per share is set, and XOMA’s common stock no longer trades on Nasdaq.
Ligand completed its previously announced acquisition of XOMA Royalty, acquiring all outstanding XOMA shares.
Stock reaction is likely already reflected around deal timing; incremental impact now is mainly about integration and CVR overhang.
The article confirms completion but provides no new financial terms beyond what was previously announced, so incremental price discovery may be modest.
Market effects
Biotech royalty aggregator M&A remains active; CVR structures highlight ongoing litigation-linked contingent economics.
Primarily US-listed biotech/biopharma capital markets impact.
Limited global spillover; mostly affects US biotech royalty and licensing ecosystem participants.
Counterpoint
LGND’s incremental upside may be muted because the article adds no new deal economics, and CVR litigation outcomes are uncertain.
Key entities
- companyXOMA Royalty Corporation
Biotechnology royalty aggregator being acquired; its Nasdaq trading ended after deal close.
- companyLigand Pharmaceuticals Incorporated
Acquirer that completed the acquisition of XOMA Royalty and took ownership of all outstanding shares.
- security_featureContingent Value Right (CVR)
Non-transferable CVR per share entitling holders to a portion of net proceeds from certain pending litigation.
